US 11,981,752 B2
Tumor associated monocyte/macrophage binding peptide and methods of use thereof
Hongbo Pang, La Jolla, CA (US); and Erkki Ruoslahti, La Jolla, CA (US)
Assigned to Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
Appl. No. 16/607,043
Filed by Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA (US)
PCT Filed May 1, 2018, PCT No. PCT/US2018/030498
§ 371(c)(1), (2) Date Jun. 11, 2020,
PCT Pub. No. WO2018/204392, PCT Pub. Date Nov. 8, 2018.
Claims priority of provisional application 62/500,224, filed on May 2, 2017.
Prior Publication US 2020/0190142 A1, Jun. 18, 2020
Int. Cl. A61K 38/00 (2006.01); A61K 38/04 (2006.01); A61K 47/69 (2017.01); C07K 7/06 (2006.01)
CPC C07K 7/06 (2013.01) [A61K 47/6911 (2017.08); A61K 38/00 (2013.01)] 47 Claims
 
1. A composition comprising an isolated peptide comprising an activated macrophage targeting (AMT) amino acid sequence,
wherein the AMT amino acid sequence has a length of 7 to 15 residues, and the formula X1-R-X2-L-R—S-X3,
wherein X1 and X3 are each, independently, zero to four amino acids,
wherein X2 is one or two amino acids,
wherein the amino acids of X1, X2, and X3 can be any amino acid,
wherein the peptide selectively binds to activated macrophages via the AMT amino acid sequence,
wherein the composition further comprises a co-composition, and
wherein the peptide and the co-composition are not covalently coupled and/or associated with each other.